883 research outputs found
Basic kinetic wealth-exchange models: common features and open problems
We review the basic kinetic wealth-exchange models of Angle [J. Angle, Social
Forces 65 (1986) 293; J. Math. Sociol. 26 (2002) 217], Bennati [E. Bennati,
Rivista Internazionale di Scienze Economiche e Commerciali 35 (1988) 735],
Chakraborti and Chakrabarti [A. Chakraborti, B. K. Chakrabarti, Eur. Phys. J. B
17 (2000) 167], and of Dragulescu and Yakovenko [A. Dragulescu, V. M.
Yakovenko, Eur. Phys. J. B 17 (2000) 723]. Analytical fitting forms for the
equilibrium wealth distributions are proposed. The influence of heterogeneity
is investigated, the appearance of the fat tail in the wealth distribution and
the relaxation to equilibrium are discussed. A unified reformulation of the
models considered is suggested.Comment: Updated version; 9 pages, 5 figures, 2 table
Preparing for pandemic influenza: the need for enhanced surveillance.
Link_to_subscribed_fulltex
Fractional diffusion in periodic potentials
Fractional, anomalous diffusion in space-periodic potentials is investigated.
The analytical solution for the effective, fractional diffusion coefficient in
an arbitrary periodic potential is obtained in closed form in terms of two
quadratures. This theoretical result is corroborated by numerical simulations
for different shapes of the periodic potential. Normal and fractional spreading
processes are contrasted via their time evolution of the corresponding
probability densities in state space. While there are distinct differences
occurring at small evolution times, a re-scaling of time yields a mutual
matching between the long-time behaviors of normal and fractional diffusion
Operationalising FRAM in Healthcare: A critical reflection on practice
Resilience Engineering principles are becoming increasingly popular in healthcare to improve patient safety. FRAM is the best-known Resilience Engineering method with several examples of its application in healthcare available. However, the guidance on how to apply FRAM leaves gaps, and this can be a potential barrier to its adoption and potentially lead to misuse and disappointing results. The article provides a self-reflective analysis of FRAM use cases to provide further methodological guidance for successful application of FRAM to improve patient safety. Five FRAM use cases in a range of healthcare settings are described in a structured way including critical reflection by the original authors of those studies. Individual reflections are synthesised through group discussion to identify lessons for the operationalisation of FRAM in healthcare. Four themes are developed: (1) core characteristics of a FRAM study, (2) flexibility regarding the underlying epistemological paradigm, (3) diversity with respect to the development of interventions, and (4) model complexity. FRAM is a systems analysis method that offers considerable flexibility to accommodate different epistemological positions, ranging from realism to phenomenology. We refer to these as computational FRAM and reflexive FRAM, respectively. Prac-titioners need to be clear about their analysis aims and their analysis position. Further guidance is needed to support practitioners to tell a convincing and meaningful "system story" through the lens of FRAM
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions is an effective and safe treatment for patients with multiple myeloma relasing or progressing after stem cell transplantation
Fractional Fokker-Planck dynamics: Numerical algorithm and simulations
Anomalous transport in a tilted periodic potential is investigated
numerically within the framework of the fractional Fokker-Planck dynamics via
the underlying CTRW. An efficient numerical algorithm is developed which is
applicable for an arbitrary potential. This algorithm is then applied to
investigate the fractional current and the corresponding nonlinear mobility in
different washboard potentials. Normal and fractional diffusion are compared
through their time evolution of the probability density in state space.
Moreover, we discuss the stationary probability density of the fractional
current values.Comment: 10 pages, 9 figure
Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: the g.I.T.m.o. Experience.
Infliximab treatment for steroid-refractory acute graft-versus-host disease
Background and Objectives. Tumor necrosis factor \u3b1 is one of the principal cytokines involved in the pathogenesis of acute graft-versus-host- disease (GVHD). Infliximab is an antibody to this cytokine. Design and Methods. We performed a retrospective analysis to evaluate the activity of infliximab in 32 patients with severe steroid-refractory acute GVHD. The patients received a median of 3 weekly courses of infliximab. The main organs involved in the patients were skin (n=2) liver (n=1), bowel (n=19), liver and bowel at the same stage (n=10). Results. Nineteen out 32 patients (59%) responded to infliximab with 6 (19%) complete and 13 (40%) partial responses. Age younger than 35 years, intestinal involvement and a longer time between hematopoietic stem cell transplantation and infliximab administration were factors predicting a favorable response. Infective episodes developed in 23/32 (72%) patients. All the 13 unresponsive patients died of GVHD shortly after infliximab. Thirteen of 19 responsive patients were alive at a median follow-up of 449 days (range 155-842) after infliximab, with no signs of chronic GVHD (n=5), limited (n=5) or extensive involvement (n=3). Six patients who responded subsequently died, one of chronic lung GVHD, the others of vascular complications or infections (2 fungal diseases). Interpretation and Conclusions. We conclude that infliximab is active in the treatment of severe steroid-refractory acute GVHD, particularly when the intestine is involved. Infections commonly followed its administration. The clinical activity of infliximab and the possibility that it increases the risk of infections are worth investigating in prospective trials
Pretransplantation 18F-Fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-hodgkin lymphoma undergoing reduced-intensity conditioning follone by allogeneic stem cell transplantation
Background: The use of positron emission tomography (PET) scanning in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (HG-NHL) has recognized prognostic value in patients who are receiving chemotherapy or undergoing autologous stem cell transplantation (SCT). In contrast, the role of PET before reduced-intensity conditioning (RIC) and followed by allogeneic SCT has not been investigated to date. Methods: PET was used to assess 80 patients who had chemosensitive disease (34 patients with HG-NHL and 46 patients with HL) before they underwent allogeneic SCT: 42 patients had negative PET studies, and 38 patients had positive PET studies. Patients underwent allograft from matched related siblings (n = 41) or alternative donors (n = 39). Results: At the time of the last follow-up, 48 patients were alive (60%), and 32 had died. The 3-year cumulative incidence of nonrecurrence mortality and disease recurrence was 17% and 40%, respectively. The cumulative incidence of disease recurrence was significantly lower in the PET-negative patients (25% vs 56%; P =.007), but there was no significant difference between the patients with or without chronic graft-versus-host disease (P =.400). The patients who had negative PET studies before undergoing allogenic SCT also had significantly better outcomes in terms of 3-year overall survival (76% vs 33%; P =.001) and 3-year progression-free survival (73% vs 31%; P =.001). On multivariate analysis, overall survival was influenced by PET status (hazard ratio [HR], 3.35), performance status (HR, 5.15), and type of donor (HR, 6.26 for haploidentical vs sibling; HR, 1.94 for matched unrelated donor vs sibling). Conclusions: The current results indicated that PET scanning appears to be an accurate tool for assessing prognosis in patients who are eligible for RIC allografting
- …